American Century Companies Inc. Boosts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

American Century Companies Inc. increased its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 2.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 44,619 shares of the company’s stock after buying an additional 1,187 shares during the period. American Century Companies Inc.’s holdings in Moderna were worth $1,855,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Allworth Financial LP boosted its stake in shares of Moderna by 17.3% during the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock worth $73,000 after acquiring an additional 281 shares in the last quarter. Howard Capital Management Inc. raised its holdings in Moderna by 3.1% in the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock worth $416,000 after purchasing an additional 297 shares during the period. Commonwealth Equity Services LLC boosted its position in Moderna by 0.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company’s stock worth $3,099,000 after purchasing an additional 345 shares in the last quarter. Larson Financial Group LLC grew its holdings in Moderna by 39.1% in the fourth quarter. Larson Financial Group LLC now owns 1,266 shares of the company’s stock valued at $53,000 after purchasing an additional 356 shares during the period. Finally, New Insight Wealth Advisors increased its position in shares of Moderna by 4.4% in the fourth quarter. New Insight Wealth Advisors now owns 8,545 shares of the company’s stock valued at $355,000 after buying an additional 358 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Down 3.9 %

Shares of Moderna stock opened at $24.64 on Wednesday. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $170.47. The firm’s 50 day moving average is $32.51 and its two-hundred day moving average is $41.91. The firm has a market capitalization of $9.53 billion, a P/E ratio of -2.66 and a beta of 2.23.

Analyst Ratings Changes

A number of research analysts have recently issued reports on MRNA shares. Barclays lowered Moderna from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. Berenberg Bank increased their price objective on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a report on Thursday, January 16th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $40.00 target price on shares of Moderna in a research report on Tuesday, February 18th. The Goldman Sachs Group downgraded shares of Moderna from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $99.00 to $51.00 in a research report on Wednesday, January 29th. Finally, Argus cut Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Four investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $59.00.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.